‘Friendly Breakup’: Sanofi And Regeneron Agree Equity Revamp
Pair Say Stock Move Will Not Hurt Their Drug Development Pact
Sanofi to sell most of its Regeneron stake, with much of it being re-purchased by Regeneron, but both stressed the move would not hurt their long established and very profitable drug-development collaboration.
You may also be interested in...
Sanofi Upbeat On Itepekimab, Rilzabrutinib And Oral IRAK4 Protein Degrader
Sanofi outlines progress on developing a differentiated R&D pipeline in immunology, including novel ways of addressing COPD, atopic dermatitis and autoimmune disorders.
Finance Watch: CureVac’s IPO Is Ready For Launch
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Sanofi Impacted By COVID 19 Headwinds, But Dupixent Powers Forward
Company keeps on track on for 2020 earnings target despite pandemic's hit to general medicines and vaccines sales.